Digestive Diseases and Sciences

, Volume 46, Issue 3, pp 587–596 | Cite as

REVIEW: Efficacy of Rabeprazole Once Daily for Acid-Related Disorders

  • Frank Lanza
  • Karna Dev Bardhan
  • Carlos Perdomo
  • Robert Niecestro
  • Jay Barth

Abstract

Proton-pump inhibitors (PPIs) have revolutionized the treatment of gastroesophageal reflux disease (GERD) and peptic ulcer. To evaluate the efficacy of the new PPI rabeprazole, 12 controlled clinical trials were conducted worldwide—three for each indication (erosive or ulcerative GERD healing, long-term GERD healing maintenance, duodenal ulcer healing, and gastric ulcer healing). Rabeprazole was compared to placebo, the H2-receptor antagonist ranitidine, and the PPI omeprazole. Treatment duration ranged from ≤4 weeks for duodenal ulcer to ≤6 weeks for gastric ulcer, ≤8 weeks for GERD healing, and 1 year for maintenance of GERD healing. Rabeprazole was as effective as omeprazole for each indication and significantly more effective than ranitidine for healing of GERD (87% vs 66%) and duodenal ulcer (83% vs 73%). Rabeprazole was also superior to ranitidine in providing symptom relief, particularly in GERD.

rabeprazole proton-pump inhibitors gastroesophageal reflux disease gastric ulcer duodenal ulcer 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFRENCES

  1. 1.
    Freston JW, Malagelada JR, Petersen H, McCloy RF: Critical issues in the management of gastroesophageal reflux disease. Eur J Gastroenterol Hepatol 7:577–586, 1995Google Scholar
  2. 2.
    DeVault KR: Current management of gastroesophageal reflux disease. Gastroenterologist 4:24–32, 1996Google Scholar
  3. 3.
    Lambert R: Review article: current practice and future perspectives in the management of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 11:651–662, 1997Google Scholar
  4. 4.
    Holt S: Proton-pump inhibition for acid-related disease. South Med J 84:1078–1087, 1991Google Scholar
  5. 5.
    Johnson DA: Medical therapy of GERD: current state of the art. Hosp Pract 31:135–148, 1996Google Scholar
  6. 6.
    Klinkenberg-Knol EC, Festen HPM, Meuwissen SGM. Pharmacological management of gastro-oesophageal reflux disease. Drugs 49:695–710, 1995Google Scholar
  7. 7.
    Sanders SW: Pathogenesis and treatment of acid peptic disorders: Comparison of proton pump inhibitors with other antiulcer agents. Clin Ther 18:2–34, 1996Google Scholar
  8. 8.
    NIH Consensus Development Panel. Helicobacter pylori in peptic ulcer disease. JAMA 272:65–69, 1994Google Scholar
  9. 9.
    Prakash A, Faulds D: Rabeprazole. Drugs 55:261–267, 1998Google Scholar
  10. 10.
    Mears JM, Kaplan B: Proton pump inhibitors: new drugs and indications. Am Fam Physician 53:285–292, 1996Google Scholar
  11. 11.
    Morii M, Takata H, Fujisaki H, Takeguchi N: The potency of substituted benzimidazoles such as E3810, omeprazole, Ro18-5364 to inhibit gastric H+, K+-ATPase is correlated with the rate of acid-activation of the inhibitor. Biochem Pharmacol 29:661–667, 1990Google Scholar
  12. 12.
    Fujisaki H, Shibata H, Oketani K, Murakami M, Fujimoto M, Wakabayashi T, Yamatsu I, Yamaguchi M, Sakai H, Takeguchi N: Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione. Biochem Pharmacol 42:321–328, 1991Google Scholar
  13. 13.
    Besancon M, Simon A, Sachs G, Shin JM: Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thio reagents. J Biol Chem 272:22438–22446, 1997Google Scholar
  14. 14.
    Williams MP, Sercombe J, Hamilton MI, Pounder RE: A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 12:1079–1089, 1998Google Scholar
  15. 15.
    Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, Mitchell B, Beveridge BR, Laurence BH, Gibson GG, Grant AK, Shearman DJC, Whitehead R, Buckle PJ: Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 95:903–912, 1988Google Scholar
  16. 16.
    Cloud ML, Enas N, Humphries TJ, Bassion S, Rabeprazole Study Group: Rabeprazole in treatment of acid peptic diseases. Results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). Dig Dis Sci 43:993–1000, 1998Google Scholar
  17. 17.
    Humphries TJ, Spera A, Breiter J, Farley A, Johnson D, Sabesin S, Wruble L, North American Rabeprazole Study Group: Rabeprazole sodium (E3810) once daily is superior to ranitidine 150 mg QID in the healing of erosive or ulcerative gastroesophageal reflux disease. Gastroenterology 110:A139, 1996 (abstract)Google Scholar
  18. 18.
    Dekkers CPM, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ: Double-blind, placebo-controlled comparison of rabeprazole 20 mg vs omeprazole 20 mg in the treatment of erosive or ulcerative gastroesophageal reflux disease. Aliment Pharmacol Ther 13:49–57, 1999Google Scholar
  19. 19.
    Birbara C, Breiter J, Collins D, Jaskir J, Perdomo C, Hahne W: Rabeprazole: preventing endoscopic and symptomatic relapse in erosive or ulcerative GERD. Am J Gastroenterol 93:1630, 1998 (abstract 85)Google Scholar
  20. 20.
    Caos A, Moskovitz M, Perdomo C, Niecestro R, Hahne W: Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Gastroenterology 116:A132, 1999Google Scholar
  21. 21.
    Humphries TJ, Dekkers CPM, Beker JA, Thjodleifsson B, Bardhan KD, Jaskir J, Perdomo C, Finnegan V, Bjaaland T, European Rabeprazole Study Group: Rabeprazole vs omeprazole for maintenance therapy of healed erosive GERD: Results of a 1-year multicenter trial. Am J Gastroenterol 93:1616, 1998 (abstract 30)Google Scholar
  22. 22.
    Humphries T, Dekkers C, Beker J, Thjodleifsson B, Rabeprazole GORD Study Group: Magnitude of changes in fasting serum gastrin in 211 patients taking rabeprazole 10 mg or 20 mg or omeprazole 20 mg for one year. Am J Gastroenterol 93:1637, 1998 (abstract 114)Google Scholar
  23. 23.
    Humphries TJ, Spera A, Breiter J, Caos A, Farley A, Riff D, Schwartz H, North American Rabeprazole Study Group: Rabeprazole sodium once daily is superior to ranitidine 150 mg bid in the healing of active duodenal ulcer. Gastroenterology 112:A154, 1997 (abstract)Google Scholar
  24. 24.
    Dekkers CPM, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ: Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: A European multicentre study. Aliment Pharmacol Ther 13:179–186, 1999Google Scholar
  25. 25.
    Dekkers CPM, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ, European Rabeprazole Study Group: Comparison of rabeprazole 20 mg vs omeprazole 20 mg in the treatment of active gastric ulcer-a European multicentre study. Aliment Pharmacol Ther 12:789–795, 1998Google Scholar
  26. 26.
    Blum AL: Treatment of acid-related disorders with gastric acid inhibitors: The state of the art. Digestion 47(suppl 1):3–10, 1990Google Scholar
  27. 27.
    Eriksson S, Långström G, Rikner L, Carlsson R, Naesdal J: Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: A meta-analysis. Eur J Gastroenterol Hepatol 7:467–475, 1995Google Scholar
  28. 28.
    Olbe L, Lundell L: Medical treatment of reflux esophagitis. Hepato-Gastroenterol 39:322–324, 1992Google Scholar

Copyright information

© Plenum Publishing Corporation 2001

Authors and Affiliations

  • Frank Lanza
  • Karna Dev Bardhan
  • Carlos Perdomo
  • Robert Niecestro
  • Jay Barth

There are no affiliations available

Personalised recommendations